
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly reported a robust performance in its second quarter of 2025, surpassing expectations for both revenue and earnings while also raising its full-year guidance. Notably, sales of Mounjaro outside the U.S. experienced a remarkable 60% quarter-over-quarter growth, attributed to successful launches in new markets such as Brazil, Mexico, and India. Additionally, the introduction of orforglipron presents an appealing oral option for patients seeking weight loss solutions, further positioning Lilly to expand its presence in the GLP-1 market.
Bears say
Eli Lilly faces significant downside risks, including potential pricing pressure and an unfavorable prescription trajectory for tirzepatide, which could adversely impact revenue growth. The negative performance of Zepbound prescriptions and expectations for sluggish volumetric growth in Q3 add to the company's challenges. Additionally, the emergence of competitive products like orforglipron, which has demonstrated strong efficacy, further complicates Lilly's market position and could hinder future sales projections.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares